BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

543 related articles for article (PubMed ID: 15502717)

  • 1. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.
    Tsuchiya N; Satoh S; Tada H; Li Z; Ohyama C; Sato K; Suzuki T; Habuchi T; Kato T
    Transplantation; 2004 Oct; 78(8):1182-7. PubMed ID: 15502717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.
    Tada H; Tsuchiya N; Satoh S; Kagaya H; Li Z; Sato K; Miura M; Suzuki T; Kato T; Habuchi T
    Transplant Proc; 2005 May; 37(4):1730-2. PubMed ID: 15919447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.
    Zhang X; Liu ZH; Zheng JM; Chen ZH; Tang Z; Chen JS; Li LS
    Clin Transplant; 2005 Oct; 19(5):638-43. PubMed ID: 16146556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients.
    Haufroid V; Mourad M; Van Kerckhove V; Wawrzyniak J; De Meyer M; Eddour DC; Malaise J; Lison D; Squifflet JP; Wallemacq P
    Pharmacogenetics; 2004 Mar; 14(3):147-54. PubMed ID: 15167702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms.
    Op den Buijsch RA; Christiaans MH; Stolk LM; de Vries JE; Cheung CY; Undre NA; van Hooff JP; van Dieijen-Visser MP; Bekers O
    Fundam Clin Pharmacol; 2007 Aug; 21(4):427-35. PubMed ID: 17635182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus.
    Hesselink DA; van Schaik RH; van der Heiden IP; van der Werf M; Gregoor PJ; Lindemans J; Weimar W; van Gelder T
    Clin Pharmacol Ther; 2003 Sep; 74(3):245-54. PubMed ID: 12966368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of CYP3A5 and ABCB1 Gene Polymorphisms on Tacrolimus Blood Concentration in Renal Transplant Recipients.
    Yildirim E; Şahin G; Kaltuş Z; Çolak E
    Clin Lab; 2019 Nov; 65(11):. PubMed ID: 31710427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients.
    Roy JN; Barama A; Poirier C; Vinet B; Roger M
    Pharmacogenet Genomics; 2006 Sep; 16(9):659-65. PubMed ID: 16906020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of CYP3A5 and MDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in Chinese renal transplant recipients.
    Rong G; Jing L; Deng-Qing L; Hong-Shan Z; Shai-Hong Z; Xin-Min N
    Transplant Proc; 2010 Nov; 42(9):3455-8. PubMed ID: 21094796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP3A5 polymorphisms and their effects on tacrolimus exposure in an ethnically diverse South African renal transplant population.
    Muller WK; Dandara C; Manning K; Mhandire D; Ensor J; Barday Z; Freercks R
    S Afr Med J; 2020 Jan; 110(2):159-166. PubMed ID: 32657689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients.
    Cho JH; Yoon YD; Park JY; Song EJ; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
    Transplant Proc; 2012 Jan; 44(1):109-14. PubMed ID: 22310591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism.
    Zheng H; Zeevi A; Schuetz E; Lamba J; McCurry K; Griffith BP; Webber S; Ristich J; Dauber J; Iacono A; Grgurich W; Zaldonis D; McDade K; Zhang J; Burckart GJ
    J Clin Pharmacol; 2004 Feb; 44(2):135-40. PubMed ID: 14747421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation.
    Hu YF; Qiu W; Liu ZQ; Zhu LJ; Liu ZQ; Tu JH; Wang D; Li Z; He J; Zhong GP; Zhou G; Zhou HH
    Clin Exp Pharmacol Physiol; 2006 Nov; 33(11):1093-8. PubMed ID: 17042920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients.
    Li D; Lu W; Zhu JY; Gao J; Lou YQ; Zhang GL
    J Clin Pharm Ther; 2007 Oct; 32(5):505-15. PubMed ID: 17875118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation.
    Anglicheau D; Thervet E; Etienne I; Hurault De Ligny B; Le Meur Y; Touchard G; Büchler M; Laurent-Puig P; Tregouet D; Beaune P; Daly A; Legendre C; Marquet P
    Clin Pharmacol Ther; 2004 May; 75(5):422-33. PubMed ID: 15116055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-Nucleotide Polymorphism of CYP3A5 Impacts the Exposure to Tacrolimus in Pediatric Renal Transplant Recipients: A Pharmacogenetic Substudy of the TWIST Trial.
    Billing H; Höcker B; Fichtner A; van Damme-Lombaerts R; Friman S; Jaray J; Vondrak K; Sarvary E; Dello Strologo L; Oellerich M; von Ahsen N; Tönshoff B
    Ther Drug Monit; 2017 Feb; 39(1):21-28. PubMed ID: 28030534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.
    Niioka T; Satoh S; Kagaya H; Numakura K; Inoue T; Saito M; Narita S; Tsuchiya N; Habuchi T; Miura M
    Transplantation; 2012 Nov; 94(10):1013-9. PubMed ID: 23073468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of different allelic variants of the CYP3A and ABCB1 genes on the tacrolimus pharmacokinetic profile of Chinese renal transplant recipients.
    Cheung CY; Op den Buijsch RA; Wong KM; Chan HW; Chau KF; Li CS; Leung KT; Kwan TH; de Vrie JE; Wijnen PA; van Dieijen-Visser MP; Bekers O
    Pharmacogenomics; 2006 Jun; 7(4):563-74. PubMed ID: 16753004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients.
    Zhang JJ; Liu SB; Xue L; Ding XL; Zhang H; Miao LY
    Int J Clin Pharmacol Ther; 2015 Sep; 53(9):728-36. PubMed ID: 26227094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between cyclosporine concentration and genetic polymorphisms of CYP3A5 and MDR1 during the early stage after renal transplantation.
    Azarpira N; Aghdaie MH; Behzad-Behbahanie A; Geramizadeh B; Behzadi S; Malekhoseinie SA; Raisjalal GH; Rahsaz M; Pourgholami A; Sagheb F
    Exp Clin Transplant; 2006 Jun; 4(1):416-9. PubMed ID: 16827636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.